Search | Clinical Trials Finder

Conditions: Chronic Hepatitis C
Interventions: VX-985 or matching placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Overland Park, Kansas • Baltimore, Maryland • Tacoma, Washington

Conditions: Primary Biliary Cholangitis, PBC
Interventions: Volixibat, Placebo; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 44
States / cities: Coronado, California • Los Angeles, California • Sacramento, California + 38 more

Conditions: Stroke, Acute
Interventions: Placebo, Nerinetide; Drug
Lead sponsor: NoNO Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 17
States / cities: Phoenix, Arizona • Torrance, California • Englewood, Colorado + 14 more

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Paromomycin sulfate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 14
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 7 more

Conditions: Sprain, Strain, Acute Soft Tissue Injury
Interventions: Topical Ketoprofen 10% Cream, Topical Placebo Cream; Drug
Lead sponsor: Imprimis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Morbid Obesity
Interventions: IV acetaminophen, IV normal saline; Drug
Lead sponsor: McLaren Regional Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Stress Disorders, Post-Traumatic, Stress Disorders, Traumatic, Acute
Interventions: Neuropeptide Y, Placebo; Drug · Other
Lead sponsor: New York Medical College; Other
Eligibility: 18 Years to 65 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Valhalla, New York

Conditions: Perimenopause
Interventions: Revive Product Form - Placebo Control, Revive Product Form - Active; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 37 Years to 55 Years · Female only
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Ulcerative Colitis
Interventions: Mirikizumab SC, Mirikizumab IV, Placebo SC; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 57
States / cities: Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 51 more

Conditions: Alzheimer's Disease
Interventions: Aducanumab (BIIB037), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 1,653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 59
States / cities: Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 52 more

Conditions: Diabetes Mellitus
Interventions: PATH electronic decision support tool; Other
Lead sponsor: St Elizabeth Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Covington, Kentucky

Conditions: Multiple Sclerosis
Interventions: dimethyl fumarate, montelukast, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 50
States / cities: Jonesboro, Arkansas • Carmichael, California • La Jolla, California + 46 more

Conditions: Muckle Wells Syndrome
Interventions: ACZ885, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 4 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Madison, Wisconsin

Conditions: Alzheimer Disease
Interventions: bapineuzumab, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 88 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 111
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 54 more

Conditions: Gulf War Syndrome
Interventions: Curcumin, Glutathione, Placebo; Drug · Other
Lead sponsor: South Florida Veterans Affairs Foundation for Research and Education; Federal
Eligibility: 35 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Low Back Pain
Interventions: Milnacipran, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Overactive Bladder
Interventions: Tolterodine ER, Placebo, Fesoterodine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 2,417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 102
States / cities: Enterprise, Alabama • Mobile, Alabama • Montgomery, Alabama + 85 more

Conditions: HIV-1
Interventions: 3BNC117-LS, 10-1074-LS, Sterile Saline; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Bethesda, Maryland • New York, New York

Conditions: Nonalcoholic Steatohepatitis
Interventions: Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), PTM SEMA, PTM CILO/FIR; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 175
States / cities: Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 137 more

Conditions: HIV Infections
Interventions: PGDM1400/Placebo (3mg/kg IV), PGDM1400/Placebo (10mg/kg IV), PGDM1400/Placebo (30mg/kg IV), PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV), PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV), PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV), PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV), PGDM1400 + PGT121 (MTD IV); Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Insulin Resistance
Interventions: MICARDIS® (telmisartan); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Westlake Village, California + 5 more

Conditions: Intermittent Claudication, Peripheral Artery Disease
Interventions: GFH312, Placebo; Drug · Other
Lead sponsor: Zhejiang Genfleet Therapeutics Co., Ltd.; Industry
Eligibility: 40 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Davenport, Iowa

Conditions: Long COVID, PASC Post Acute Sequelae of COVID 19
Interventions: Valacyclovir celecoxib dose 1, Valacyclovir celecoxib dose 2, Placebo; Drug
Lead sponsor: Bateman Horne Center; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Alcohol Use Disorder, Sexually Transmitted Diseases
Interventions: Standardized kudzu, Placebo, Sexually transmitted infection testing:, Medical Management (MM) counseling for alcohol use:, Urinalysis for novel alcohol biochemical markers for recent alcohol use:, Dried Blood Spot (DBS) Testing for PEth:, Behavioral survey measurements:, Ecological Momentary Assessment procedure:; Drug · Other · Diagnostic Test + 1 more
Lead sponsor: Glenn-Milo Santos; Other
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Study of VX-985 in Subjects With Chronic Hepatitis C

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3

Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury

Efficacy of IV Acetaminophen in Acute Post-Operative Pain Control in Laparoscopic Roux-en-Y Gastric Bypass Surgery (LRYGBP) Patients

Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder

Radicle Revive™ CSP: A Trial Evaluating Plant-Based Health and Wellness Products on Perimenopausal Women's Self-Reported Health Issues and Outcomes

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

Electronic Decision Support for Intervention in Poorly Controlled Type 2 Diabetes

Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome

Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

Glutathione vs. Curcumin Clinical Trial

Effect of Milnacipran in Chronic Neuropathic Low Back Pain

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults

The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects

A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)

Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

Addressing Heavy Alcohol Use Consumption With Kudzu